Asuransi Jiwa Sinarmas Msig PT (LIFE) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Asuransi Jiwa Sinarmas Msig PT stock IDR 3,468, price IDR 9,775, that is 64.5% below the price, quality 67 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 4,530 IDR – 16,878 IDR · fair‑value band 2,601 IDR – 4,335 IDR · the 9,775 IDR price screens above the 3,468 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Asuransi Jiwa Sinarmas Msig PT in your weekly email
Every Wednesday you see whether Asuransi Jiwa Sinarmas Msig PT is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT MSIG Life Insurance Indonesia Tbk provides life insurance products in Indonesia. The company operates through six segments: Term Insurance, Endowment, Whole Life Insurance, and Health Insurance.
Show moreShow less
It offers personal accident, medical, and medika ultimax; protection and unit link life insurance; and life insurance, such as smart life guard, smile berkat, income protection x-tra, bank sinarmas, bank bukopin, smile dana sejahtera, and smile pro infinite insurance products.
The company also provides group insurance; education and pension insurance; and Sharia Insurance, as well as bancassurance products. It serves individual and group customers.
The company was formerly known as PT Asuransi Jiwa Sinarmas MSIG Tbk and changed its name to PT MSIG Life Insurance Indonesia Tbk in July 2023. PT MSIG Life Insurance Indonesia Tbk was founded in 1984 and is based in Setiabudi, Indonesia.
PT MSIG Life Insurance Indonesia Tbk operates as a subsidiary of Mitsui Sumitomo Insurance Co., Ltd.
Stock analysis
Asuransi Jiwa Sinarmas Msig PT (LIFE) currently trades at 9,775 IDR, while our model-based Fair Value estimate is 3,468 IDR, 65% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 3,468 IDR per share, and 0 of the 6 models we run sit above the 9,775 IDR price.
Bear case: the Dividend Discount group reads lowest at 1,297 IDR, and 6 of the 6 models stay below the price. Data coverage for this calculation is low.
Scenario range: 2,601 IDR (bear) to 4,335 IDR (bull), the price of 9,775 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Financial Services sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Asuransi Jiwa Sinarmas Msig PT reported revenue of 3.1T IDR in FY2025 versus 4.0T IDR in FY2021, a compound −6.3%/yr. Reported net income was 206B IDR in FY2025, compounding +29.3%/yr from FY2021.
Key figures
Market cap 20.5T IDR (≈ $1.1B) Small · P/E ratio 73.5 · P/S ratio 7.51 · EPS (TTM) 133.00 IDR · Dividend yield 1.0% · Net margin 10.2% · Return on equity 3.4% · Return on assets (EBIT) 1.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 75% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Financial Services peers we cover trades at −38% fair-value upside, at −65%, LIFE screens richer than that median.
Fair Value models
Bear2,601 IDRFair Value 3,468 IDRBull4,335 IDR
Price 9,775 IDR · Downside -64.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (31.63 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−16.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.5%
Start year 2020 (pandemic). Over 10 years: −5.2% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−8.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−9.0%
Dividend (yield on the price)1.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−9.0% vs −5.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 7%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 8.1%/yr over ~9Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about +7.6% a year for the price.
Compare Asuransi Jiwa Sinarmas Msig PT with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Insurance - Life · 77 stocks
Beats the industry median on 2/13 measures
Overall it trails its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside−64.5% · Bottom 25%
Profitability
Return on equity (12 months)3.4% · Bottom 25%
Return on assets1.3% · Above median
Net margin (12 months)10.2% · Below median
Operating margin (12 months)14.1% · Below median
Growth and dividend
Revenue growth (quarter YoY)2.0% · Below median
Dividend yield (12 months)1.0% · Bottom 25%
Valuation Multiplesvs Insurance - Life median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Asuransi Jiwa Sinarmas Msig PT Fair Value". https://www.fairvalue-calculator.com/stock/LIFE
Frequently asked questions
Is Asuransi Jiwa Sinarmas Msig PT (LIFE) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 3,468 IDR versus a price of 9,775 IDR, about 65% lower (overvalued).
What is the fair value of LIFE?
Our model-based fair value for Asuransi Jiwa Sinarmas Msig PT is 3,468 IDR (as of Nov 5, 2026), built from audited fundamentals. The current price: 9,775 IDR.
What is the quality score of LIFE?
Asuransi Jiwa Sinarmas Msig PT has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Asuransi Jiwa Sinarmas Msig PT (LIFE)?
Our model-based price target is the fair value of 3,468 IDR (as of Nov 5, 2026) from 6 valuation models. Cautious scenario 2,601 IDR, optimistic scenario 4,335 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Asuransi Jiwa Sinarmas Msig PT stock forecast for 2026?
Our models put fair value at 3,468 IDR, about 65% lower versus a price of 9,775 IDR (overvalued). Cautious scenario 2,601 IDR, optimistic scenario 4,335 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Asuransi Jiwa Sinarmas Msig PT (LIFE)?
Asuransi Jiwa Sinarmas Msig PT reported trailing-twelve-month revenue of about 2.7T IDR (latest available figure, as of Nov 5, 2026).
Does Asuransi Jiwa Sinarmas Msig PT pay a dividend?
Asuransi Jiwa Sinarmas Msig PT currently shows a dividend yield of 0.98% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Asuransi Jiwa Sinarmas Msig PT (LIFE) and when is the ex-dividend date?
Asuransi Jiwa Sinarmas Msig PT pays a dividend of 96.00 IDR per share a year, a dividend yield of 1.0%. The last ex-dividend date was May 8, 2026. A dividend has been paid every year since at least 2020. The payout ratio is 72.2% of earnings. Free cash flow covers the dividend 6.09 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Asuransi Jiwa Sinarmas Msig PT (LIFE)?
For today's price to be fair in a discounted-cash-flow model, Asuransi Jiwa Sinarmas Msig PT would have to grow free cash flow by +10.5 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -6.5 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of LIFE use?
Our models discount Asuransi Jiwa Sinarmas Msig PT at 12.0 %: a base by market capitalisation (small), damped by beta 0.19, country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Asuransi Jiwa Sinarmas Msig PT that is +10.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has Asuransi Jiwa Sinarmas Msig PT (LIFE) delivered so far?
Over the past 5 years revenue at Asuransi Jiwa Sinarmas Msig PT grew -6.5 % a year. The price currently implies free-cash-flow growth of +10.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Asuransi Jiwa Sinarmas Msig PT (LIFE) growing?
The median revenue growth in the sector is +9.2 % a year. That is the yardstick for the growth priced into Asuransi Jiwa Sinarmas Msig PT (+10.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Asuransi Jiwa Sinarmas Msig PT (LIFE)?
The free-cash-flow yield on the price is 5.98 %: that much free cash flow Asuransi Jiwa Sinarmas Msig PT produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Asuransi Jiwa Sinarmas Msig PT (LIFE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Asuransi Jiwa Sinarmas Msig PT it is 3,468 IDR per share (as of Nov 5, 2026), against a price of 9,775 IDR. It is the blended result of 6 valuation models in 4 families (Dividend Discount, Multiples, Asset-Based, Economic Profit).
Is Asuransi Jiwa Sinarmas Msig PT stock overvalued or undervalued in 2026?
As of Nov 5, 2026, LIFE trades above its calculated fair value: price 9,775 IDR, fair value 3,468 IDR, a gap of about −65% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LIFE?
No. The price is what the market pays today (9,775 IDR); the fair value is what the company's own numbers justify (3,468 IDR). For Asuransi Jiwa Sinarmas Msig PT the two are 6,307 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Asuransi Jiwa Sinarmas Msig PT worth?
The market values Asuransi Jiwa Sinarmas Msig PT at about 20.5T IDR (market capitalisation, as of Nov 5, 2026). Per share that is 9,775 IDR; our models calculate a fair value of 3,468 IDR per share.
What do the bullish and bearish scenarios say about LIFE?
Our models span a range for Asuransi Jiwa Sinarmas Msig PT: cautious scenario 2,601 IDR, base 3,468 IDR, optimistic 4,335 IDR per share (as of Nov 5, 2026, price 9,775 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LIFE?
Asuransi Jiwa Sinarmas Msig PT trades at a price-to-earnings ratio of 73.5 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 3,468 IDR is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2019 to 2025), reported earnings: 43.3. Other multiples: P/B 2.4, P/S 7.5, EV/EBITDA 57.2.
How solid is the balance sheet of Asuransi Jiwa Sinarmas Msig PT (LIFE)?
Balance-sheet figures for Asuransi Jiwa Sinarmas Msig PT (as of Nov 5, 2026): return on equity 3.4%. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is LIFE from its 52-week high?
Asuransi Jiwa Sinarmas Msig PT trades at 9,775 IDR, about 23% below its 52-week high of 12,725 IDR and 75% above the low of 5,575 IDR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 3,468 IDR is for.
Which stocks are comparable to Asuransi Jiwa Sinarmas Msig PT?
From the same area (Financial Services) we also value Ping An Insurance (Group) Company, China Life Insurance Company, AIA Group, Manulife Financial Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Asuransi Jiwa Sinarmas Msig PT stock attractive at the current price?
The data as of Nov 5, 2026: price 9,775 IDR, calculated fair value 3,468 IDR (−65%), Quality Score 67/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LIFE calculated?
We run Asuransi Jiwa Sinarmas Msig PT through 6 models from 4 families: Dividend Discount, Multiples, Asset-Based, Economic Profit. Every model gets the same audited fundamentals; the fair value of 3,468 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Asuransi Jiwa Sinarmas Msig PT itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Asuransi Jiwa Sinarmas Msig PT (LIFE)?
The closing price on Nov 6, 2026 was 9,775 IDR. Our model-based fair value is 3,468 IDR, about 65% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Asuransi Jiwa Sinarmas Msig PT right now?
The price sits above even our optimistic bull case (4,335 IDR). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Key figures of Asuransi Jiwa Sinarmas Msig PT
How large is the market capitalisation of Asuransi Jiwa Sinarmas Msig PT (LIFE)?
The market capitalisation of Asuransi Jiwa Sinarmas Msig PT is 20.5T IDR (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Asuransi Jiwa Sinarmas Msig PT (LIFE)?
The price-to-sales ratio of Asuransi Jiwa Sinarmas Msig PT is 7.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Asuransi Jiwa Sinarmas Msig PT (LIFE)?
Earnings per share at Asuransi Jiwa Sinarmas Msig PT are 133.00 IDR (price ÷ EPS = P/E 73.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Asuransi Jiwa Sinarmas Msig PT (LIFE)?
The dividend yield of Asuransi Jiwa Sinarmas Msig PT is 1.0% (payout 72.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Asuransi Jiwa Sinarmas Msig PT (LIFE)?
The net margin of Asuransi Jiwa Sinarmas Msig PT is 10.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Asuransi Jiwa Sinarmas Msig PT (LIFE)?
The return on equity (ROE) of Asuransi Jiwa Sinarmas Msig PT is 3.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Asuransi Jiwa Sinarmas Msig PT (LIFE)?
On an EBIT basis the return on assets of Asuransi Jiwa Sinarmas Msig PT is 1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Asuransi Jiwa Sinarmas Msig PT (LIFE)?
The operating margin of Asuransi Jiwa Sinarmas Msig PT is 14.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Asuransi Jiwa Sinarmas Msig PT (LIFE)?
Revenue at Asuransi Jiwa Sinarmas Msig PT is growing +2.0% versus a year earlier (3y avg −3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Asuransi Jiwa Sinarmas Msig PT (LIFE)?
Earnings per share at Asuransi Jiwa Sinarmas Msig PT are growing +3.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Asuransi Jiwa Sinarmas Msig PT (LIFE) hold?
Asuransi Jiwa Sinarmas Msig PT holds more cash than debt, 986B IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Asuransi Jiwa Sinarmas Msig PT in the live analysis
One click puts Asuransi Jiwa Sinarmas Msig PT on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026